COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease.
Location: United States, Illinois, Skokie
Total raised: $135M
Investors 2
| Date | Name | Website |
| 08.02.2024 | Lumira Ven... | lumiravent... |
| - | Alpha Wave... | alphawaveg... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 30.01.2024 | Series A | $105M | Lumira Ven... |
| 07.09.2022 | - | $30M | - |
Mentions in press and media 7
| Date | Title | Description | Source |
| 30.01.2024 | COUR Pharmaceuticals Secures $105 Million in Series A Financ... | CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) — COUR Pharmaceuticals, a clinical-stage biotechnology compa... | lumiravent... |
| 30.01.2024 | Cour Pharmaceuticals, a biotech taking aim at autoimmune dis... | John Puisis was dubious when he first heard about the autoimmune science being developed by a coalit... | statnews.c... |
| 30.01.2024 | Cour Pharmaceuticals Closes Approximately $105M Series A Fun... | Cour Pharmaceuticals, a Chicago, IL-based clinical-stage biotechnology company, raised approximately... | finsmes.co... |
| 30.01.2024 | Cour Pharmaceuticals lands $105 million for next phase of cl... | - | bizjournal... |
| 07.09.2022 | Cour Pharmaceuticals Raises $30M in Funding | Cour Pharmaceuticals, a Chicago, IL-based clinical-stage biotechnology company developing novel immu... | finsmes.co... |
| - | Cour Pharmaceuticals Development | “Reprogramming the Immune System About COUR Who We Are COUR Pharmaceuticals is developing first-in-c... | fastfounde... |
| - | Cour Pharmaceuticals Development | “COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system... | fastfounde... |